

Hutchison Whampoa Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 013)

OVERSEAS REGULATORY ANNOUNCEMENT

Please refer to the attached announcement of Hutchison China MediTech Limited, which is listed on the Alternative Investment Market operated by the London Stock Exchange and a 71.6% owned subsidiary of Hutchison Whampoa Limited.

As at the date of the announcement, the Directors of Hutchison Whampoa Limited are:

Executive Directors:

Mr. LI Ka-shing (*Chairman*)
Mr. LI Tzar Kuoi, Victor (*Deputy Chairman*)
Mr. FOK Kin-ning, Canning
Mrs. CHOW WOO Mo Fong, Susan
Mr. Frank John SIXT
Mr. LAI Kai Ming, Dominic
Mr. KAM Hing Lam

Non-executive Directors:

Mr. George Colin MAGNUS
Mr. William SHURNIAK

Independent Non-executive Directors:

The Hon. Sir Michael David KADOORIE
Mr. Holger KLUGE
Mr. William Elkin MOCATTA
(Alternate to The Hon. Sir Michael David Kadoorie)
Mr. Simon MURRAY
Mr. OR Ching Fai, Raymond
Mr. WONG Chung Hin
(also Alternate to Mr. Simon Murray)

Hong Kong, 11 May 2007



HUTCHISON CHINA MEDITECH LTD

**Hutchison China MediTech Limited ("Chi-Med")
(AIM: HCM)**

Results of Annual General Meeting

London, Friday, 11 May 2007: Chi-Med is pleased to announce that all ordinary resolutions put to its Annual General Meeting ("AGM") held on 11 May 2007 were duly passed and the poll results of the resolutions were as follows:

Ordinary Resolutions		Number of Votes (%)		
		For	Against	Withheld
1	To receive and consider the audited financial statements and the reports of the directors and independent auditor for the year ended 31 December 2006.	40,537,607 (100%)	0 (0%)	0 (0%)
2(a)	To re-elect Mr. Christian Hogg as a director.	40,437,607 (100%)	0 (0%)	0 (0%)
2(b)	To re-elect Mr. Patrick Wan as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
2(c)	To re-elect Mr. Christian Salbaing as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
2(d)	To re-elect Ms. Edith Shih as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
2(e)	To re-elect Mr. Michael Howell as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
2(f)	To re-elect Prof. Christopher Huang as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
2(g)	To re-elect Mr. Christopher Nash as a director.	40,537,607 (100%)	0 (0%)	0 (0%)
3	To re-appoint PricewaterhouseCoopers as the auditor of the Company and authorise the board of directors to fix the auditor's remuneration.	40,537,607 (100%)	0 (0%)	0 (0%)
4(a)	Ordinary resolution on item 4(A) of the Notice of the Meeting (To grant a general mandate to the directors of the Company to issue additional shares)	40,537,607 (100%)	0 (0%)	0 (0%)

4(b)	Ordinary resolution on item 4(B) of the Notice of the Meeting (To grant a general mandate to the directors of the Company to repurchase shares of the Company)	40,537,607 (100%)	0 (0%)	0 (0%)
5	Ordinary resolution on item 5 of the Notice of the Meeting (To extend the general mandate to the directors of the Company to issue additional shares)	40,537,607 (100%)	0 (0%)	0 (0%)

As at the date of the AGM, the number of issued shares of Chi-Med was 51,212,121 shares, which was the total number of shares entitling the holders to attend and vote on the resolutions proposed at the AGM.

Ends

Enquiries

Citigate Dewe Rogerson Telephone: +44 (0) 20 7638 9571

Anthony Carlisle +44 (0) 7973 611 888

Yvonne Alexander +44 (0) 7866 610 682

About Chi-Med

Chi-Med is the holding company of a pharmaceutical and healthcare group based primarily in China and was admitted to trading on the Alternative Investment Market of the London Stock Exchange in May 2006. Chi-Med is focused on researching, developing, manufacturing, and selling pharmaceuticals, health supplements and other consumer health and personal care products derived from Traditional Chinese Medicine and botanical ingredients.

Chi-Med is majority owned by Hutchison Whampoa Limited, an international corporation listed on the Main Board of The Stock Exchange of Hong Kong Limited.